If you had PMOS — polyendocrine metabolic ovarian syndrome, the condition most of us still know as PCOS — in your 20s and 30s, here’s something almost nobody tells you heading into your 40s: menopause doesn’t reset your metabolic risk to baseline. It adds to it.
That’s not the same claim as “PMOS risk continues after menopause,” which has gotten some recent attention. It’s a more specific mechanistic point, and it’s the one that actually changes how this decade should be managed: perimenopause is an independent insulin-resistance event for every woman, PMOS history or not. When it happens to a woman whose insulin resistance was already elevated for the previous two decades, the two don’t just add — they compound.
Hit one: PMOS insulin resistance doesn’t go away
For the 50-70% of women with PMOS (PCOS) who experience insulin resistance, that resistance isn’t a reproductive-years-only phenomenon that resolves once cycles become less relevant. It persists. Fasting glucose, HbA1c, and insulin levels typically stay elevated well past the reproductive years, reflecting ongoing metabolic dysfunction rather than something tied specifically to ovulatory function. If you were borderline insulin resistant at 28, you’re not automatically fine at 45 just because the PMOS diagnosis feels like ancient history — or because it was still called PCOS when you first heard it.
Hit two: perimenopause is its own insulin-resistance event
Independent of any PMOS history, the menopausal transition itself drives insulin resistance in essentially every woman. Estrogen has real protective metabolic effects — on insulin sensitivity, fat distribution, and vascular function — and as estrogen declines through perimenopause, those protections erode. Abdominal fat mass increases even without significant weight gain, which is itself a marker of the metabolic shift underway rather than just an aesthetic change.
Why the combination is worse than either alone
This is the part that gets missed in most coverage of either topic separately: when menopausal insulin resistance lands on top of a pre-existing PMOS-related insulin resistance, the risk of triggering full metabolic syndrome is measurably higher than either factor would produce on its own. This isn’t two independent risks running in parallel — it’s a compounding effect, where the reproductive-years condition determines how much reserve capacity you have left when the second hit arrives. [likely]
What this means practically
If you’re a woman with a PMOS (PCOS) history heading into your 40s, the useful question isn’t “is my old diagnosis still relevant.” It’s “how much metabolic reserve do I actually have going into a transition that’s going to test it regardless.” That’s a very different framing than either “manage your PMOS” or “manage your menopause symptoms” treated as separate problems — which is how almost all existing content, mine included, has historically split this.
Next in this series: what actually shows up differently — clinically, not just theoretically — when PMOS-history women go through perimenopause compared to women without that history.
Medical Disclaimer
The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health‑care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.
Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.